We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Agilent Technologies to Acquire Assets of iLab Solutions

By LabMedica International staff writers
Posted on 04 Jul 2016
Agilent Technologies Inc. More...
(Santa Clara, California, USA) will acquire most of the assets of iLab Solutions, LLC (Boston, Massachusetts, USA), including the company’s technology, intellectual property, product portfolio and employee talent. The acquisition is expected to be completed in early August, subject to local laws and regulations and customary closing conditions.

Agilent provides instruments, software, services and consumables for the entire laboratory workflow to customers in more than 100 countries, while iLab offers cloud-based solutions for core laboratory management to universities, research hospitals and independent institutes. iLab’s offerings allow customers to book time in shared facilities to bill and invoice for projects, manage studies, generate reports and business intelligence, and schedule instrument reservations across multiple projects.

“Our acquisition of iLab further expands our offerings portfolio in a space we previously did not have a presence in,” said Mark Doak, president, Agilent CrossLab Group. “iLab’s solutions are robust and scalable, allowing for expansion into large-enterprise accounts, including Pharma. With iLab’s experience and outstanding enterprise-level management solutions, we will be able to immediately deliver broader value for our customers.”

“Joining forces with Agilent is an excellent fit for us,” said Tad Fallows, chief executive officer, iLab Solutions. “It is also a tremendous opportunity for our customers, who will benefit from integration with a broad family of solutions and a range of new applications. Together, we’ll be able to further accelerate our offerings to additional markets through Agilent’s global reach and leadership in multiple market segments.”

Related Links:
Agilent Technologies
iLab Solutions

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Thyroid Test
Anti-Thyroid EIA Test
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.